SAR97276A

Phase 2Terminated
0 watching 0 views this week Active
51
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Malaria

Conditions

Malaria

Trial Timeline

Aug 1, 2008 → Jun 1, 2009

About SAR97276A

SAR97276A is a phase 2 stage product being developed by Sanofi for Malaria. The current trial status is terminated. This product is registered under clinical trial identifier NCT00739206. Target conditions include Malaria.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00739206Phase 2Terminated